Related Experiment Video

Updated: Feb 23, 2026

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study
02:35

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Published on: March 22, 2024

1.6K

Identification of a p53 target, CD137L, that mediates growth suppression and immune response of osteosarcoma cells

Yusuke Tsuda1,2, Chizu Tanikawa3, Takafumi Miyamoto1,3

  • 1Laboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, University of Tokyo, Tokyo, Japan.

Scientific Reports
|September 8, 2017
PubMed

Insights

p53 regulates tumor suppression by activating genes like CD137L. This study identifies novel p53 targets, including CD137L, which suppress osteosarcoma growth and activate immune responses, offering therapeutic potential.

Area of Science:

  • Molecular Biology
  • Oncology
  • Immunology

Background:

  • The tumor suppressor p53 is frequently mutated in osteosarcoma, but its precise role in osteosarcoma development remains unclear.
  • Understanding p53's function in osteosarcomagenesis is crucial for identifying new therapeutic targets.

Purpose of the Study:

  • To comprehensively identify p53-target genes in calvarial bone.
  • To discover novel, druggable p53 target genes for osteosarcoma treatment.
  • To investigate the therapeutic potential of identified p53 target genes.

Main Methods:

  • RNA sequencing was performed on calvarial bone and 23 other tissues from irradiated p53 wild-type and knockout mice.
  • Pathway analysis was used to identify enriched gene sets among p53-induced genes.
  • The growth-suppressive effects of novel p53 target genes on osteosarcoma cell lines were evaluated in vitro and in vivo.

Main Results:

  • Radiation exposure induced 69 genes and repressed 127 genes in p53 wild-type calvarial bone.
  • Genes involved in cytokine-cytokine receptor interactions were significantly enriched.
  • CD137L, CDC42 binding protein kinase gamma, and Follistatin were identified as novel direct p53 target genes with growth-suppressive effects on osteosarcoma cells.
  • CD137L, specifically induced in calvarial bone, demonstrated in vivo growth suppression and activated immune responses.

Conclusions:

  • CD137L is a novel p53 target gene with significant potential for osteosarcoma therapy.
  • CD137L exerts growth-suppressive effects on osteosarcoma cells and modulates the immune response.
  • This study elucidates the role of CD137L in osteosarcomagenesis and highlights its therapeutic applicability.

More Related Videos

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.3K
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

7.5K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.6K